KORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. It offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company also provides education and training materials to clinicians, patients, and patient advocates. It sells its products through direct sales and medical device distributors, as well as online. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York.
Company profile
Ticker
KRMD
Exchange
Website
CEO
Ms. Linda M. Tharby
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
REPRO MED SYSTEMS INC
SEC CIK
Corporate docs
IRS number
133044880
KRMD stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
21 Aug 24
8-K
Koru Medical Systems, Inc. Announces 2024 Q2 Financial Results, a Record Quarter with 22% Revenue Growth; Raises Full Year 2024 Guidance
7 Aug 24
10-Q
2024 Q2
Quarterly report
7 Aug 24
8-K
Entry into a Material Definitive Agreement
24 Jul 24
S-8
Registration of securities for employees
10 Jul 24
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Jul 24
8-K
Changes in Registrant's Certifying Accountant
3 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
14 May 24
10-Q
2024 Q1
Quarterly report
1 May 24
8-K
Koru Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-digit Revenue Growth
1 May 24
Transcripts
KRMD
Earnings call transcript
2024 Q2
7 Aug 24
KRMD
Earnings call transcript
2024 Q1
1 May 24
KRMD
Earnings call transcript
2023 Q4
13 Mar 24
KRMD
Earnings call transcript
2023 Q3
8 Nov 23
KRMD
Earnings call transcript
2023 Q2
9 Aug 23
KRMD
Earnings call transcript
2023 Q2
9 Aug 23
KRMD
Earnings call transcript
2023 Q1
4 May 23
KRMD
Earnings call transcript
2022 Q4
8 Mar 23
KRMD
Earnings call transcript
2022 Q3
12 Nov 22
KRMD
Earnings call transcript
2022 Q2
7 Aug 22
Latest ownership filings
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 10.46 mm | 10.46 mm | 10.46 mm | 10.46 mm | 10.46 mm | 10.46 mm |
Cash burn (monthly) | 120.77 k | 105.12 k | 397.34 k | 595.16 k | (no burn) | 34.45 k |
Cash used (since last report) | 536.94 k | 467.34 k | 1.77 mm | 2.65 mm | n/a | 153.17 k |
Cash remaining | 9.92 mm | 9.99 mm | 8.69 mm | 7.81 mm | n/a | 10.30 mm |
Runway (months of cash) | 82.1 | 95.0 | 21.9 | 13.1 | n/a | 299.1 |
Institutional ownership, Q2 2024
54.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 66 |
Opened positions | 24 |
Closed positions | 16 |
Increased positions | 11 |
Reduced positions | 21 |
13F shares | Current |
---|---|
Total value | 38.00 bn |
Total shares | 25.14 mm |
Total puts | 300.00 |
Total calls | 0.00 |
Total put/call ratio | Infinity |
Largest owners | Shares | Value |
---|---|---|
Horton Capital Partners | 8.06 mm | $19.75 mm |
First Light Asset Management | 5.04 mm | $13.35 bn |
Topline Capital Management | 2.74 mm | $6.14 mm |
Vanguard | 1.78 mm | $4.72 bn |
Archon Capital Management | 1.05 mm | $2.78 bn |
Meros Investment Management | 804.38 k | $2.13 bn |
RBF Capital | 798.45 k | $2.12 bn |
Albion Financial | 705.28 k | $1.87 bn |
Millennium Management | 469.67 k | $1.24 bn |
Geode Capital Management | 433.81 k | $1.15 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Oct 24 | Robert Cascella | Common Stock | Grant | Acquire A | No | No | 2.75 | 5,454 | 15.00 k | 70,978 |
1 Oct 24 | Fletcher R John | Common Stock | Grant | Acquire A | No | No | 2.75 | 8,181 | 22.50 k | 190,851 |
1 Oct 24 | Shahriar Matin | Common Stock | Grant | Acquire A | No | No | 2.75 | 5,454 | 15.00 k | 73,608 |
1 Oct 24 | Wholihan Edward | Common Stock | Grant | Acquire A | No | No | 2.75 | 5,454 | 15.00 k | 23,776 |
1 Oct 24 | Donna French | Common Stock | Grant | Acquire A | No | No | 2.75 | 5,454 | 15.00 k | 70,978 |
Press releases
KORU Medical Systems to Participate in Upcoming Investor Conferences
6 Nov 24
KORU Medical Systems Presents Data at Partnership Opportunities in Drug Delivery (PODD) Conference Demonstrating Nursing Preference for Use of KORU FreedomEdge® Infusion System over Manual Syringe Administration for Subcutaneous Oncology Infusion
31 Oct 24
KORU Medical Systems to Participate in the 8th Annual Lake Street Best Ideas Growth Conference
5 Sep 24